However, GLP-1 agonists like semaglutide have more established long-term safety data
Type 2 diabetes mellitus: a review of multi-target drugs
The absence of validated efficacy data means youre titrating based on subjective experience and hope, not on a known dose-response curve
Whether grey-market semaglutide delivers the same benefits depends entirely on whether it actually contains what it claims to contain at the stated concentration, which brings us right back to the quality question that defines the grey-market experience
Adverse events reported through postmarketing surveillance outside of the United States included inflammatory reaction, inflammatory nodule, unsatisfactory result, loss/lack of correction, allergic reaction, anxiety, vascular occlusion, infection, dry skin, increase/decrease in sensation, and abscess